Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31412285 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL10690383 | 0.91 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL2750480 | 0.85 | ALDH1A1 (0.74) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL10827980 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL3093813 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL31332120 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL10827864 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL3171933 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL15669005 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL9850770 | 0.81 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691842-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-04-06 | — | — | US | disclosed |
| CN-100506825-C | Heterotricyclyl 6-alkylidene-penems as beta epsilontaualpha-lactamase inhibitors | WYETH CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| EP-1499622-B1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | WYETH CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1885358-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007030166-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D β-LACTAMASES INHIBITORS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7018997-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1649882-A | Heterotricyclyl 6-alkylidene-penems as beta epsilontaualpha-lactamase inhibitors | WYETH CORP (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1499622-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH | 2004-03-04 | — | — | US | disclosed |
| WO-2003093280-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS ΒΕΤΑ-LACTAMASE INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | SMN1; SMN2 1450/4885NPC1 800/4885RAB9A 1712/4885 |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | SMN1; SMN2 2433/4885NPC1 1676/4885RAB9A 2490/4885 |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, MGAM, PREP | SMN1; SMN2 2433/4885NPC1 1676/4885RAB9A 2490/4885 |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, PGLS, MGAM | SMN1; SMN2 4284/4885NPC1 2769/4885RAB9A 2285/4885 |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | SMN1; SMN2 2305/4885NPC1 1423/4885RAB9A 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.